JP2012517818A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012517818A5 JP2012517818A5 JP2011550552A JP2011550552A JP2012517818A5 JP 2012517818 A5 JP2012517818 A5 JP 2012517818A5 JP 2011550552 A JP2011550552 A JP 2011550552A JP 2011550552 A JP2011550552 A JP 2011550552A JP 2012517818 A5 JP2012517818 A5 JP 2012517818A5
- Authority
- JP
- Japan
- Prior art keywords
- variable domain
- single variable
- tnfr1
- seq
- dom7h
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 102100033732 Tumor necrosis factor receptor superfamily member 1A Human genes 0.000 claims 14
- 101710187743 Tumor necrosis factor receptor superfamily member 1A Proteins 0.000 claims 12
- 125000003275 alpha amino acid group Chemical group 0.000 claims 8
- 108060003951 Immunoglobulin Proteins 0.000 claims 6
- 102000018358 immunoglobulin Human genes 0.000 claims 6
- 239000003446 ligand Substances 0.000 claims 5
- 102000007562 Serum Albumin Human genes 0.000 claims 4
- 108010071390 Serum Albumin Proteins 0.000 claims 4
- 239000005557 antagonist Substances 0.000 claims 4
- 241000282567 Macaca fascicularis Species 0.000 claims 3
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims 3
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims 3
- 238000003556 assay Methods 0.000 claims 3
- 230000005764 inhibitory process Effects 0.000 claims 3
- 102000039446 nucleic acids Human genes 0.000 claims 3
- 108020004707 nucleic acids Proteins 0.000 claims 3
- 150000007523 nucleic acids Chemical class 0.000 claims 3
- 241000282465 Canis Species 0.000 claims 2
- 101100425753 Homo sapiens TNFRSF1A gene Proteins 0.000 claims 2
- 102000004890 Interleukin-8 Human genes 0.000 claims 2
- 108090001007 Interleukin-8 Proteins 0.000 claims 2
- 238000010494 dissociation reaction Methods 0.000 claims 2
- 230000005593 dissociations Effects 0.000 claims 2
- 230000004968 inflammatory condition Effects 0.000 claims 2
- 239000002773 nucleotide Substances 0.000 claims 2
- 125000003729 nucleotide group Chemical group 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 108020003175 receptors Proteins 0.000 claims 2
- 102000005962 receptors Human genes 0.000 claims 2
- 230000028327 secretion Effects 0.000 claims 2
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 claims 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 206010003246 arthritis Diseases 0.000 claims 1
- 230000003013 cytotoxicity Effects 0.000 claims 1
- 231100000135 cytotoxicity Toxicity 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 230000036963 noncompetitive effect Effects 0.000 claims 1
- 229920001184 polypeptide Polymers 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US15374609P | 2009-02-19 | 2009-02-19 | |
| US61/153,746 | 2009-02-19 | ||
| US24119809P | 2009-09-10 | 2009-09-10 | |
| US61/241,198 | 2009-09-10 | ||
| PCT/EP2010/052005 WO2010094720A2 (en) | 2009-02-19 | 2010-02-17 | Improved anti-tnfr1 polypeptides, antibody variable domains & antagonists |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015151376A Division JP2016007218A (ja) | 2009-02-19 | 2015-07-31 | 改善された抗ｔｎｆｒ１ポリペプチド、抗体可変ドメインおよびアンタゴニスト |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2012517818A JP2012517818A (ja) | 2012-08-09 |
| JP2012517818A5 true JP2012517818A5 (enExample) | 2013-03-07 |
Family
ID=42136168
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011550552A Pending JP2012517818A (ja) | 2009-02-19 | 2010-02-17 | 改善された抗ｔｎｆｒ１ポリペプチド、抗体可変ドメインおよびアンタゴニスト |
| JP2015151376A Pending JP2016007218A (ja) | 2009-02-19 | 2015-07-31 | 改善された抗ｔｎｆｒ１ポリペプチド、抗体可変ドメインおよびアンタゴニスト |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015151376A Pending JP2016007218A (ja) | 2009-02-19 | 2015-07-31 | 改善された抗ｔｎｆｒ１ポリペプチド、抗体可変ドメインおよびアンタゴニスト |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20110301335A1 (enExample) |
| EP (1) | EP2398827A2 (enExample) |
| JP (2) | JP2012517818A (enExample) |
| KR (1) | KR20110119806A (enExample) |
| CN (1) | CN102405236A (enExample) |
| AU (1) | AU2010215479B2 (enExample) |
| BR (1) | BRPI1008014A2 (enExample) |
| CA (1) | CA2750477A1 (enExample) |
| EA (1) | EA022925B1 (enExample) |
| IL (1) | IL214648A0 (enExample) |
| MX (1) | MX2011008799A (enExample) |
| SG (1) | SG173173A1 (enExample) |
| WO (1) | WO2010094720A2 (enExample) |
| ZA (1) | ZA201105627B (enExample) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9028822B2 (en) * | 2002-06-28 | 2015-05-12 | Domantis Limited | Antagonists against TNFR1 and methods of use therefor |
| SG173489A1 (en) * | 2009-02-19 | 2011-09-29 | Glaxo Group Ltd | Improved anti-serum albumin binding variants |
| WO2011008814A2 (en) * | 2009-07-14 | 2011-01-20 | Immune Tolerance Institute, Inc., A California Not-For-Profit Corporation | Multiplexed measurement of exogenous and endogenous dna |
| CA2768460A1 (en) * | 2009-07-16 | 2011-01-20 | Glaxo Group Limited | Antagonists, uses & methods for partially inhibiting tnfr1 |
| ES2552177T3 (es) * | 2009-10-27 | 2015-11-26 | Glaxo Group Limited | Polipéptidos anti-TNFR1 estables, dominios variables de anticuerpos y antagonistas |
| JP2013529080A (ja) * | 2010-05-20 | 2013-07-18 | グラクソ グループ リミテッド | 改良された抗血清アルブミン結合変異体 |
| WO2012035141A1 (en) | 2010-09-16 | 2012-03-22 | Baliopharm Ag | Anti-hutnfr1 antibody |
| US20140112929A1 (en) * | 2011-06-17 | 2014-04-24 | Glaxo Group Limited | Tumour necrosis factor receptor 1 antagonists |
| WO2015104322A1 (en) | 2014-01-09 | 2015-07-16 | Glaxosmithkline Intellectual Property Development Limited | Treatment of inflammatory diseases with non-competitive tnfr1 antagonists |
| US9107906B1 (en) | 2014-10-28 | 2015-08-18 | Adma Biologics, Inc. | Compositions and methods for the treatment of immunodeficiency |
| WO2016094309A1 (en) * | 2014-12-10 | 2016-06-16 | Myosotis | Inhibition of tnf signaling in cancer immunotherapy |
| NO2768984T3 (enExample) * | 2015-11-12 | 2018-06-09 | ||
| CN107043413A (zh) * | 2016-02-05 | 2017-08-15 | 华中农业大学 | 一种肺结核相关的尿液生物标志蛋白及其应用 |
| US10259865B2 (en) | 2017-03-15 | 2019-04-16 | Adma Biologics, Inc. | Anti-pneumococcal hyperimmune globulin for the treatment and prevention of pneumococcal infection |
| WO2020158858A1 (ja) * | 2019-01-31 | 2020-08-06 | 積水メディカル株式会社 | 生物学的試料中の遊離ａｉｍの免疫学的分析方法及び対象におけるｎａｓｈの検出方法 |
| WO2020172218A1 (en) | 2019-02-21 | 2020-08-27 | Enosi Life Sciences Corp. | Antibodies and enonomers |
| IL300930A (en) | 2020-08-27 | 2023-04-01 | Enosi Therapeutics Corp | Methods and compositions for the treatment of autoimmune diseases and cancer |
| WO2022117569A1 (en) | 2020-12-02 | 2022-06-09 | Oncurious Nv | A ccr8 antagonist antibody in combination with a lymphotoxin beta receptor agonist antibody in therapy against cancer |
| WO2025021184A1 (zh) * | 2023-07-27 | 2025-01-30 | 上海复宏汉霖生物医药有限公司 | 编码尿酸氧化酶的多核苷酸及其相关组合物和方法 |
| WO2025049818A1 (en) | 2023-08-29 | 2025-03-06 | Enosi Therapeutics Corporation | Tnfr1 antagonists lacking agonist activity and uses thereof |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3101690B2 (ja) | 1987-03-18 | 2000-10-23 | エス・ビィ・２・インコーポレイテッド | 変性抗体の、または変性抗体に関する改良 |
| GB8725529D0 (en) | 1987-10-30 | 1987-12-02 | Delta Biotechnology Ltd | Polypeptides |
| WO1989007142A1 (en) | 1988-02-05 | 1989-08-10 | Morrison Sherie L | Domain-modified constant region antibodies |
| DE768377T1 (de) | 1988-09-02 | 1998-01-02 | Dyax Corp | Herstellung und Auswahl von Rekombinantproteinen mit verschiedenen Bindestellen |
| ATE92107T1 (de) | 1989-04-29 | 1993-08-15 | Delta Biotechnology Ltd | N-terminale fragmente von menschliches serumalbumin enthaltenden fusionsproteinen. |
| US5977307A (en) | 1989-09-07 | 1999-11-02 | Alkermes, Inc. | Transferrin receptor specific ligand-neuropharmaceutical agent fusion proteins |
| US6172197B1 (en) | 1991-07-10 | 2001-01-09 | Medical Research Council | Methods for producing members of specific binding pairs |
| WO1994026087A2 (en) | 1993-05-14 | 1994-11-24 | Connor Kim C O | Recombinant protein production and insect cell culture and process |
| AU691811B2 (en) | 1993-06-16 | 1998-05-28 | Celltech Therapeutics Limited | Antibodies |
| EP2258846A3 (en) | 1997-07-07 | 2012-03-21 | Medical Research Council | A method for increasing the concentration of a nucleic acid molecule |
| IL127127A0 (en) | 1998-11-18 | 1999-09-22 | Peptor Ltd | Small functional units of antibody heavy chain variable regions |
| CA2399388A1 (en) | 2000-02-11 | 2001-08-16 | Michael J. Lenardo | Identification of a domain in the tumor necrosis factor receptor family that mediates pre-ligand receptor assembly and function |
| ATE477280T1 (de) | 2001-06-28 | 2010-08-15 | Domantis Ltd | Doppelspezifischer ligand und dessen verwendung |
| WO2005077042A2 (en) | 2004-02-09 | 2005-08-25 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| EP1572936A2 (en) | 2002-03-05 | 2005-09-14 | Eli Lilly And Company | Heterologous g-csf fusion proteins |
| CA2492092A1 (en) | 2002-06-28 | 2004-01-08 | Greg Winter | Immunoglobin single variant antigen-binding domains and dual-specific constructs |
| US7696320B2 (en) | 2004-08-24 | 2010-04-13 | Domantis Limited | Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor |
| US9321832B2 (en) | 2002-06-28 | 2016-04-26 | Domantis Limited | Ligand |
| US20060002935A1 (en) * | 2002-06-28 | 2006-01-05 | Domantis Limited | Tumor Necrosis Factor Receptor 1 antagonists and methods of use therefor |
| CA2505325C (en) | 2002-11-08 | 2014-02-25 | Ablynx N.V. | Stabilized single domain antibodies |
| GB0230203D0 (en) | 2002-12-27 | 2003-02-05 | Domantis Ltd | Fc fusion |
| EP1578801A2 (en) | 2002-12-27 | 2005-09-28 | Domantis Limited | Dual specific single domain antibodies specific for a ligand and for the receptor of the ligand |
| EP2357237A1 (en) | 2003-05-14 | 2011-08-17 | Domantis Limited | A process for recovering polypeptides that unfold reversibly from a polypeptide repertoire |
| PT1639011E (pt) | 2003-06-30 | 2009-01-20 | Domantis Ltd | Anticorpos (dab) de domínio único peguilados |
| PL1737962T3 (pl) | 2004-03-24 | 2011-02-28 | Domantis Ltd | Uniwersalny lider GAS1 |
| GB0418651D0 (en) | 2004-08-20 | 2004-09-22 | Medical Res Council | Method |
| CN101084014A (zh) * | 2004-10-08 | 2007-12-05 | 杜门蒂斯有限公司 | 抗肿瘤坏死因子受体1的单域抗体及其使用方法 |
| GB0521621D0 (en) | 2005-10-24 | 2005-11-30 | Domantis Ltd | Tumor necrosis factor receptor 1 antagonists for treating respiratory diseases |
| EA200801170A1 (ru) * | 2005-12-01 | 2008-12-30 | Домантис Лимитед | Форматы неконкурентного доменного антитела, которые связываются с рецептором интерлейкина 1 первого типа |
| AU2006323412A1 (en) * | 2005-12-06 | 2007-06-14 | Domantis Limited | Ligands that have binding specificity for EGFR and/or VEGF and methods of use therefor |
| GB0724331D0 (en) | 2007-12-13 | 2008-01-23 | Domantis Ltd | Compositions for pulmonary delivery |
| EA200901494A1 (ru) * | 2007-06-06 | 2010-06-30 | Домантис Лимитед | Способы селекции протеазоустойчивых полипептидов |
| US7868885B2 (en) | 2007-06-22 | 2011-01-11 | Microsoft Corporation | Direct manipulation of subdivision surfaces using a graphics processing unit |
| CN102574914A (zh) * | 2009-07-16 | 2012-07-11 | 葛兰素集团有限公司 | 改进的抗血清清蛋白结合性单可变区 |
| CA2768460A1 (en) * | 2009-07-16 | 2011-01-20 | Glaxo Group Limited | Antagonists, uses & methods for partially inhibiting tnfr1 |
| ES2552177T3 (es) * | 2009-10-27 | 2015-11-26 | Glaxo Group Limited | Polipéptidos anti-TNFR1 estables, dominios variables de anticuerpos y antagonistas |
-
2010
- 2010-02-17 KR KR1020117021824A patent/KR20110119806A/ko not_active Ceased
- 2010-02-17 JP JP2011550552A patent/JP2012517818A/ja active Pending
- 2010-02-17 US US13/202,349 patent/US20110301335A1/en not_active Abandoned
- 2010-02-17 CA CA2750477A patent/CA2750477A1/en not_active Abandoned
- 2010-02-17 MX MX2011008799A patent/MX2011008799A/es not_active Application Discontinuation
- 2010-02-17 WO PCT/EP2010/052005 patent/WO2010094720A2/en not_active Ceased
- 2010-02-17 EP EP10704151A patent/EP2398827A2/en not_active Withdrawn
- 2010-02-17 AU AU2010215479A patent/AU2010215479B2/en not_active Ceased
- 2010-02-17 BR BRPI1008014A patent/BRPI1008014A2/pt not_active IP Right Cessation
- 2010-02-17 SG SG2011054459A patent/SG173173A1/en unknown
- 2010-02-17 EA EA201190116A patent/EA022925B1/ru not_active IP Right Cessation
- 2010-02-17 CN CN2010800173301A patent/CN102405236A/zh active Pending
-
2011
- 2011-07-29 ZA ZA2011/05627A patent/ZA201105627B/en unknown
- 2011-08-15 IL IL214648A patent/IL214648A0/en unknown
-
2015
- 2015-07-31 JP JP2015151376A patent/JP2016007218A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012517818A5 (enExample) | ||
| JP7641968B2 (ja) | Ｉｌ－１３およびｔｓｌｐを標的化する免疫グロブリン単一可変ドメインを含むポリペプチド | |
| JP2010530220A5 (enExample) | ||
| JP6475712B2 (ja) | サイトカインアンタゴニストの標的化 | |
| US9708402B2 (en) | Anti-BAFF-anti-IL-17 bispecific antibodies | |
| JP2009539349A5 (enExample) | ||
| JP2009511579A5 (enExample) | ||
| JP2017500018A5 (enExample) | ||
| CN109311974A (zh) | 抗人白细胞介素-17a单克隆抗体、其制备方法和应用 | |
| JP2012070740A5 (enExample) | ||
| JP2012532619A5 (enExample) | ||
| JP2012021001A5 (enExample) | ||
| JP2009521909A5 (enExample) | ||
| JP2019521647A5 (enExample) | ||
| JP2019522961A5 (enExample) | ||
| JP2011526792A5 (enExample) | ||
| JP2018521691A5 (enExample) | ||
| JP2014500009A5 (enExample) | ||
| JP2009518005A5 (enExample) | ||
| HRP20150799T1 (hr) | Sastavi i postupci za protutijela protiv komplementnog proteina c5 | |
| JP2012528110A5 (enExample) | ||
| RU2018100129A (ru) | Способы лечения подагры | |
| JP2008501716A5 (enExample) | ||
| JP2014503209A5 (enExample) | ||
| ES2822431T3 (es) | Polipéptidos de unión a IL-17A |